Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Five Prime Therapeutics Inc.

www.fiveprime.com

Latest From Five Prime Therapeutics Inc.

Bookmark
  • News

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

By Mandy Jackson
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs
Bookmark
  • News

Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks

By Mandy Jackson

Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.

Financing StartUps and SMEs
Bookmark
  • Analysis

Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy

By Joseph Haas

Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.

Business Strategies Deals
Bookmark
  • Analysis

Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses

By Brian Yang

Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.

Financing Hong Kong
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • FivePrime Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Five Prime Therapeutics Inc.
  • Senior Management
  • William Ringo, Interim CEO
    Francis Sarena, Chief Strategy Officer and Secretary
    Helen Collins, MD, SVP, CMO
  • Contact Info
  • Five Prime Therapeutics Inc.
    Phone: (415) 365-5600
    111 Oyster Point Blvd.
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By